Vaginal atrophy, also known as urogenital atrophy or atrophic vaginitis, is the inflammation of the vagina. It is the result of the vaginal tissues getting shrunken and thinned out. The most common cause of vaginal atrophy is the lack of estrogen, the female reproductive hormone. Vaginal atrophy can be caused during perimenopause and can get aggravated in the postmenopausal phase.
Scope of the Report:
This report focuses on the Postmenopausal Vaginal Atrophy Treatment in EMEA market, covering Europe, Middle East and Africa, This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Pfizer
Allergan
Shionogi
Novo Nordisk
Teva Pharmaceutical
Bayer.
Market Segment by Regions, regional analysis covers
Europe (Germany, France, UK, Russia, Italy and Turkey)
Middle East (Saudi Arabia, Israel, UAE and Iran)
Africa (South Africa, Nigeria, Egypt and Algeria)
Market Segment by Type, covers
Creams
Tablets
Patches
Rings
Market Segment by Applications, can be divided into
Topical Estrogen
Systemic Estrogen
Non-hormonal Therapy
There are 13 Chapters to deeply display the EMEA Postmenopausal Vaginal Atrophy Treatment market.
Chapter 1, to describe Postmenopausal Vaginal Atrophy Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Postmenopausal Vaginal Atrophy Treatment, with sales, revenue, and price of Postmenopausal Vaginal Atrophy Treatment, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the EMEA market by regions, with sales, revenue and market share of Postmenopausal Vaginal Atrophy Treatment, for each region, from 2012 to 2017;
Chapter 5, 6, 7, to analyze the market by regions, manufacturers, type and application, with sales, revenue and market share by key countries in these regions;
Chapter 8 and 9, to show the market by type and application, with sales market share and growth rate by type, application, from 2012 to 2017;
Chapter 10, Postmenopausal Vaginal Atrophy Treatment market forecast, by regions, type and application, with sales and revenue, from 2017 to 2022;
Chapter 11, 12 and 13, to describe Postmenopausal Vaginal Atrophy Treatment research findings and conclusion, sales channel, distributors, traders, dealers, appendix and data source
Frequently Asked Questions
These dominant industry players use well planned strategies to occupied highest market share in this market. Some of the top players in [Keyword] business includes.
[Company list]
As per [Keyword] market analysis, North America is forecasted to occupied major share in the [Keyword] market.
The statistical data of the dominant industry player of [Keyword] market can be acquired from the company profile segment described in the report. This segment come up with analysis of major player’s in the [Keyword] market, also their last five-year revenue, segmental, product offerings, key strategies adopted and geographical revenue produced.
The report come up with a segment of the [Keyword] market based on Type, Region, and Application, Also offer a determined view on the [Keyword] market.
The report offers a nitty-gritty estimation of the market by providing data on various viewpoints that incorporate, restraints, drivers, and opportunities threats. This data can help in making suitable decisions for stakeholders before investing.
The sample report for [Keyword] market can be received after the apply from the website.
Table Of Content
Table of Contents
1 Market Overview
1.1 Postmenopausal Vaginal Atrophy Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Creams
1.2.2 Tablets
1.2.3 Patches
1.2.4 Rings
1.3 Market Analysis by Applications
1.3.1 Topical Estrogen
1.3.2 Systemic Estrogen
1.3.3 Non-hormonal Therapy
1.4 Market Analysis by Regions
1.4.1 Europe (Germany, France, UK, Italy, Russia and Turkey)
1.4.1.1 Germany Market States and Outlook (2012-2022)
1.4.1.2 France Market States and Outlook (2012-2022)
1.4.1.3 UK Market States and Outlook (2012-2022)
1.4.1.4 Italy Market States and Outlook (2012-2022)
1.4.1.5 Russia Market States and Outlook (2012-2022)
1.4.1.6 Turkey Market States and Outlook (2012-2022)
1.4.2 Middle East (Saudi Arabia, Israel, UAE and Iran)
1.4.2.1 Saudi Arabia Market States and Outlook (2012-2022)
1.4.2.2 UAE Market States and Outlook (2012-2022)
1.4.2.3 Israel Market States and Outlook (2012-2022)
1.4.2.4 Iran Market States and Outlook (2012-2022)
1.4.3 Africa (South Africa, Nigeria, Egypt and Algeria)
1.4.3.1 South Africa Market States and Outlook (2012-2022)
1.4.3.2 Nigeria Market States and Outlook (2012-2022)
1.4.3.3 Egypt Market States and Outlook (2012-2022)
1.4.3.4 Algeria Market States and Outlook (2012-2022)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 Postmenopausal Vaginal Atrophy Treatment Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Pfizer Postmenopausal Vaginal Atrophy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Allergan
2.2.1 Business Overview
2.2.2 Postmenopausal Vaginal Atrophy Treatment Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Allergan Postmenopausal Vaginal Atrophy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Shionogi
2.3.1 Business Overview
2.3.2 Postmenopausal Vaginal Atrophy Treatment Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Shionogi Postmenopausal Vaginal Atrophy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novo Nordisk
2.4.1 Business Overview
2.4.2 Postmenopausal Vaginal Atrophy Treatment Type and Applications
2.4.2.1 Type 1
2.4.2.2 Type 2
2.4.3 Novo Nordisk Postmenopausal Vaginal Atrophy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Teva Pharmaceutical
2.5.1 Business Overview
2.5.2 Postmenopausal Vaginal Atrophy Treatment Type and Applications
2.5.2.1 Type 1
2.5.2.2 Type 2
2.5.3 Teva Pharmaceutical Postmenopausal Vaginal Atrophy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Bayer.
2.6.1 Business Overview
2.6.2 Postmenopausal Vaginal Atrophy Treatment Type and Applications
2.6.2.1 Type 1
2.6.2.2 Type 2
2.6.3 Bayer. Postmenopausal Vaginal Atrophy Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 EMEA Postmenopausal Vaginal Atrophy Treatment Market Competition, by Manufacturer
3.1 EMEA Postmenopausal Vaginal Atrophy Treatment Sales and Market Share by Manufacturer
3.2 EMEA Postmenopausal Vaginal Atrophy Treatment Revenue and Market Share by Manufacturer
3.3 EMEA Postmenopausal Vaginal Atrophy Treatment Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Postmenopausal Vaginal Atrophy Treatment Manufacturer Market Share
3.4.2 Top 5 Postmenopausal Vaginal Atrophy Treatment Manufacturer Market Share
3.5 Market Competition Trend
4 EMEA Postmenopausal Vaginal Atrophy Treatment Market Analysis by Regions
4.1 EMEA Postmenopausal Vaginal Atrophy Treatment Sales, Revenue and Market Share by Regions
4.1.1 EMEA Postmenopausal Vaginal Atrophy Treatment Sales by Regions (2012-2017)
4.1.2 EMEA Postmenopausal Vaginal Atrophy Treatment Revenue by Regions (2012-2017)
4.2 Europe Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
4.3 Middle East Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
4.4 Africa Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
5 Europe Postmenopausal Vaginal Atrophy Treatment by Countries, Type, Application and Manufacturers
5.1 Europe Postmenopausal Vaginal Atrophy Treatment Sales, Revenue and Market Share by Countries
5.1.1 Europe Postmenopausal Vaginal Atrophy Treatment Sales by Countries (2012-2017)
5.1.2 Europe Postmenopausal Vaginal Atrophy Treatment Revenue by Countries (2012-2017)
5.1.3 Germany Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
5.1.4 France Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
5.1.5 UK Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
5.1.6 Russia Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
5.1.7 Italy Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
5.1.8 Turkey Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
5.2 Europe Postmenopausal Vaginal Atrophy Treatment Sales and Revenue (value) by Manufacturers (2016-2017)
5.2.1 Europe Postmenopausal Vaginal Atrophy Treatment Sales by Manufacturers (2016-2017)
5.2.2 Europe Postmenopausal Vaginal Atrophy Treatment Revenue by Manufacturers (2016-2017)
5.3 Europe Postmenopausal Vaginal Atrophy Treatment Sales by Type (2012-2017)
5.4 Europe Postmenopausal Vaginal Atrophy Treatment Sales by Application (2012-2017)
6 Middle East Postmenopausal Vaginal Atrophy Treatment by Countries, Type, Application and Manufacturers
6.1 Middle East Postmenopausal Vaginal Atrophy Treatment Sales, Revenue and Market Share by Countries
6.1.1 Middle East Postmenopausal Vaginal Atrophy Treatment Sales by Countries (2012-2017)
6.1.2 Middle East Postmenopausal Vaginal Atrophy Treatment Revenue by Countries (2012-2017)
6.1.3 Saudi Arabia Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
6.1.4 Israel Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
6.1.5 UAE Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
6.1.6 Iran Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
6.2 Middle East Postmenopausal Vaginal Atrophy Treatment Sales and Revenue (value) by Manufacturers (2016-2017)
6.2.1 Middle East Postmenopausal Vaginal Atrophy Treatment Sales by Manufacturers (2016-2017)
6.2.2 Middle East Postmenopausal Vaginal Atrophy Treatment Revenue by Manufacturers (2016-2017)
6.3 Middle East Postmenopausal Vaginal Atrophy Treatment Sales by Type (2012-2017)
6.4 Middle East Postmenopausal Vaginal Atrophy Treatment Sales by Application (2012-2017)
7 Africa Postmenopausal Vaginal Atrophy Treatment by Countries, Type, Application and Manufacturers
7.1 Africa Postmenopausal Vaginal Atrophy Treatment Sales, Revenue and Market Share by Countries
7.1.1 Africa Postmenopausal Vaginal Atrophy Treatment Sales by Countries (2012-2017)
7.1.2 Africa Postmenopausal Vaginal Atrophy Treatment Revenue by Countries (2012-2017)
7.1.3 South Africa Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
7.1.4 Nigeria Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
7.1.5 Egypt Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
7.1.6 Algeria Postmenopausal Vaginal Atrophy Treatment Sales and Growth (2012-2017)
7.2 Middle East Postmenopausal Vaginal Atrophy Treatment Sales and Revenue (value) by Manufacturers (2016-2017)
7.2.1 Middle East Postmenopausal Vaginal Atrophy Treatment Sales by Manufacturers (2016-2017)
7.2.2 Middle East Postmenopausal Vaginal Atrophy Treatment Revenue by Manufacturers (2016-2017)
7.3 Middle East Postmenopausal Vaginal Atrophy Treatment Sales by Type (2012-2017)
7.4 Middle East Postmenopausal Vaginal Atrophy Treatment Sales by Application (2012-2017)
8 EMEA Postmenopausal Vaginal Atrophy Treatment Market Segment by Type
8.1 EMEA Postmenopausal Vaginal Atrophy Treatment Sales, Revenue and Market Share by Type (2012-2017)
8.1.1 EMEA Postmenopausal Vaginal Atrophy Treatment Sales and Market Share by Type (2012-2017)
8.1.2 EMEA Postmenopausal Vaginal Atrophy Treatment Revenue and Market Share by Type (2012-2017)
8.2 Creams Sales Growth and Price
10.2.1 EMEA Creams Sales Growth (2012-2017)
10.2.2 EMEA Creams Price (2012-2017)
8.3 Tablets Sales Growth and Price
10.3.1 EMEA Tablets Sales Growth (2012-2017)
10.3.2 EMEA Tablets Price (2012-2017)
8.4 Patches Sales Growth and Price
10.4.1 EMEA Patches Sales Growth (2012-2017)
10.4.2 EMEA Patches Price (2012-2017)
8.5 Rings Sales Growth and Price
10.5.1 EMEA Rings Sales Growth (2012-2017)
10.5.2 EMEA Rings Price (2012-2017)
9 EMEA Postmenopausal Vaginal Atrophy Treatment Market Segment by Application
9.1 EMEA Postmenopausal Vaginal Atrophy Treatment Sales Market Share by Application (2012-2017)
9.2 Topical Estrogen Sales Growth (2012-2017)
9.3 Systemic Estrogen Sales Growth (2012-2017)
9.4 Non-hormonal Therapy Sales Growth (2012-2017)
10 EMEA Postmenopausal Vaginal Atrophy Treatment Market Forecast (2017-2022)
10.1 EMEA Postmenopausal Vaginal Atrophy Treatment Sales, Revenue and Growth Rate (2017-2022)
10.2 Postmenopausal Vaginal Atrophy Treatment Market Forecast by Regions (2017-2022)
10.2.1 Europe Postmenopausal Vaginal Atrophy Treatment Market Forecast by Regions (2017-2022)
10.2.1.1 Germany Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.1.2 France Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.1.3 UK Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.1.4 Russia Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.1.5 Italy Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.1.6 Turkey Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.2 Middle East Market Forecast by Regions (2017-2022)
10.2.2.1 Saudi Arabia Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.2.2 Israel Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.2.3 UAE Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.2.4 Iran Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.3 Africa Market Forecast by Regions (2017-2022)
10.2.3.1 South Africa Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.3.2 Nigeria Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.3.3 Egypt Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.2.3.4 Algeria Postmenopausal Vaginal Atrophy Treatment Sales Forecast 2017-2022
10.3 Postmenopausal Vaginal Atrophy Treatment Market Forecast by Type (2017-2022)
10.4 Postmenopausal Vaginal Atrophy Treatment Market Forecast by Application (2017-2022)
11 Sales Channel, Distributors, Traders and Dealers
11.1 Sales Channel
11.1.1 Direct Marketing
11.1.2 Indirect Marketing
11.1.3 Marketing Channel Future Trend
11.2 Distributors, Traders and Dealers
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology
13.2 Analyst Introduction
13.3 Data Source
Inquiry For Buying
EMEA Postmenopausal Vaginal Atrophy Treatment
Please fill out the form. We will contact you within 24 hours:
All fields required...
Request Sample
EMEA Postmenopausal Vaginal Atrophy Treatment
Please fill out the form. We will contact you within 24 hours:
All fields required...
